부산대학교 도서관

Objectives Tissue factor (TF) exposed on activated monocytes and macrophages is involved in thrombosis through activation of factor X and cytokine release, responsible for inflammation and thrombosis. We investigated the effect of two anti-factor Xa drugs: rivaroxaban, a direct anti-Xa inhibitor, and fondaparinux, an antithrombin dependent anti-Xa inhibitor, on monocyte/macrophage procoagulant activity and cytokine release. Methods Rivaroxaban and fondaparinux were tested at pharmacological concentrations on LPS-activated monocytes and on THP-1 cells, a human monocytic cell line, to assess 1) TF expression by flow cytometry 2) prothrombinase activity by its coagulant activity and 3) cytokine release in cell supernatants by antibody based cytokine array and ELISA for IL-8 and TNF[alpha]. Results and conclusion Rivaroxaban and fondaparinux did not modify TF expression level on activated cells. In contrast procoagulant activity associated to monocytes and macrophages was dose dependently inhibited by rivaroxaban, but not significantly by fondaparinux. These results could explain why patients undergoing major orthopedic surgery with rivaroxaban prophylaxis were able to achieve significant reductions in venous thromboembolism, compared with drugs commonly used, i.e. fondaparinux and low molecular weight heparin. In addition, rivaroxaban and fondaparinux suppressed some chemokine secretion produced by activated macrophages. This may also contribute to their antithrombotic effect in clinic. Keywords: Coagulant, Fondaparinux, Rivaroxaban, Monocyte, Cytokine
Author(s): Marc Laurent[sup.1] , Ulrich Joimel[sup.1] , Rñmi Varin[sup.1,2] , Lionel Cazin[sup.1] , Caroline Gest[sup.1] , Veronique Le-Cam-Duchez[sup.1] , Jian Jin[sup.3,4] , Jielin Liu[sup.3,5] , Jean-Pierre Vannier[sup.1] , He Lu[sup.3] [...]